AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

#### LISTING OF CLAIMS:

1. (currently amended): A compound represented by the following formula (I):

$$\begin{array}{c|c}
R^1 & R^3 \\
\hline
 N-N-Ar-X-G
\end{array} (I)$$

wherein R<sup>1</sup> represents hydrogen;

R<sup>2</sup> represents hydrogen, alkyl, amino, halogen, halogenoalkenyl, earboxyl, alkoxycarbonyl, earbamoyl, *N*, dialkylearbamoyl, *N* hydroxyalkylearbamoyl, aryl selected from the group consisting of phenyl, naphthyl, anthryl, phenanthryl and biphenylyl, which has a substituent, or a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxycarbonyl, carboxyalkoxy, alkoxycarbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl,

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

N,N-dialkylaminoalkylcarbonyl, carboxyalkyl, alkoxycarbonylalkoxy, morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, N-alkylaminosulfonyl, N,N-dialkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, N-alkylaminosulfonylalkyl, N,N-dialkylaminosulfonylalkyl, aralkyl, alkylsulfonylamino, N-alkylaminosulfonylamino, N,N-dialkylaminosulfonylamino, N-alkylaminoacylamino, N,N-dialkylaminoacylamino, N,N-dialkylaminoacylamino,

a group represented by the following formula (II):

$$-A^{1}-Y^{1}$$
 (II)

wherein  $A^1$  represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and  $Y^1$  represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y<sup>1</sup> is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, N-alkylamino, N,N-dialkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkyl-N-alkoxycarbonylamino and N-alkyl-N-alkoxycarbonylaminoalkyl,

a group represented by the following formula (III)

$$-A^2$$
-(C=O)-Y<sup>2</sup> (III)

wherein A<sup>2</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y<sup>2</sup> represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

wherein the substituent on Y<sup>2</sup> represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, N-alkylamino, N,N-dialkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkyl-N-alkoxycarbonylamino and N-alkyl-N-alkoxycarbonylaminoalkyl,

a group represented by the following formula (IV)

$$-A^3-N(R^4)(R^5)$$
 (IV)

wherein A<sup>3</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-(C=O)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group; and R<sup>4</sup> and R<sup>5</sup> each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, or alkyldiphenylsilyloxyalkyl, and

a group represented by the following formula (V)

$$-A^4$$
-(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>) (V)

wherein A<sup>4</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

R<sup>6</sup> and R<sup>7</sup> each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*,*N*-dialkylaminoalkylcarbonyl, *N*,*N*-dialkylaminoalkylcarbonyl or alkyldiphenylsilyloxyalkyl;

R<sup>3</sup> represents hydrogen;

Ar represents phenylene, which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond; and

G represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein said heterocyclic group is selected from furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, tetrahydroquinolyl, tetrahydrothiazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidiazopyridyl and tetrahydroimidazopyridyl, and wherein the substituent is one or 2 or 3 substituents, which are the same or different, selected from Group (C): halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxycarbonyl, N-alkylamino, N,N-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl,

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahvdropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, pyrrolidinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group selected from the group consisting of indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, 4H-quinolizinyl, quinazolinyl, dihydroquinazolinyl, tetrahydroquinazolinyl, cinnolinyl, tetrahydrocinnolinyl, indolizinyl, tetrahydroindolizinyl, benzothiazolyl, tetrahydrobenzothiazolyl, benzosothiazolyl, benzoisothiazolyl, benzoisothiazolyl, benzoimidazolyl, naphthyridinyl, tetrahydronaphthyridinyl, thienopyridyl, tetrahydrothienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, thiazolopyridazinyl, tetrahydrothiazolopyridazinyl, pyrrolopyridyl, dihydropyrrolopyridyl, tetrahydropyrrolopyridyl, pyrrolopyrimidinyl, dihydropyrrolopyrimidinyl, pyridopyrimidinyl, tetrahydropyridopyrimidinyl, pyranothiazolyl, dihydropyranothiazolyl, furopyridyl, tetrahydrofuropyridyl, oxazolopyridyl, tetrahydrooxazolopyridyl, oxazolopyridazinyl, tetrahydrooxazolopyridazinyl, pyrrolothiazolyl, dihydropyrrolothiazolyl, pyrrolooxazolyl, dihydropyrrolooxazolyl, thienopyrrolyl, thiazolopyrimidinyl, thiazolooxazolyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, tetrahydroimidazopyridyl, pyrazinopyridazinyl, imidazotriazinyl, oxazolopyridyl, benzooxepinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl, benzotriazepinyl, thienoazepinyl, tetrahydrothienoazepinyl, thienodiazepinyl, thienotriazepinyl, thiazoloazepinyl, and tetrahydrothiazoloazepinyl, which may have a substituent, wherein the substituent represents one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (C):

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q90666

Application No.: 10/551,414

Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, *N*-alkylamino, *N*,*N*-dialkylamino, *N*-alkylaminoalkyl, *N*,*N*-dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof.

2.-9. (canceled).

10. (previously presented): A pharmaceutical composition which comprises the compound represented by formula (I) according to claim 1, or a salt thereof, and a pharmaceutically acceptable carrier.

### 11.-13. (canceled).

14. (previously presented): An agent for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises the compound represented by formula (I) according to claim 1, or a salt thereof.

15.-27. (canceled).

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Application No.: 10/551,414

28. (withdrawn-currently amended): A method for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises administering a compound represented by formula (I):

$$\begin{array}{c|c}
R^1 & R^3 \\
\hline
 N-N-Ar-X-G
\end{array} (I)$$

wherein

R<sup>1</sup> represents hydrogen;

R<sup>2</sup> represents hydrogen, alkyl, amino, halogen, halogenoalkenyl, carboxyl, alkoxycarbonyl, carbamoyl, *N*,*N*-dialkylcarbamoyl, *N*-hydroxyalkylcarbamoyl, aryl selected from the group consisting of phenyl, naphthyl, anthryl, phenanthryl and biphenylyl, which has a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxycarbonyl, carboxyalkoxy, alkoxycarbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl, *N*,*N*-dialkylaminoalkylcarbonyl, carboxyalkyl, alkoxycarbonylalkoxy,

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, *N*-alkylaminosulfonylalkyl, *N*,*N*-dialkylaminosulfonylamino, *N*-alkylaminosulfonylamino, *N*,*N*-dialkylaminosulfonylamino, *N*-alkylaminosulfonylamino, *N*,*N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino,

a group represented by the following formula (II):

$$-A^1-Y^1$$
 (II)

wherein A<sup>1</sup> represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and Y<sup>1</sup> represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y<sup>1</sup> is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, N-alkylamino, N,N-dialkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkyl-N-alkoxycarbonylamino and N-alkyl-N-alkoxycarbonylaminoalkyl,

a group represented by the following formula (III)

$$-A^2$$
-(C=O)-Y<sup>2</sup> (III)

wherein A<sup>2</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y<sup>2</sup> represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y<sup>2</sup> represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl,

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Application No.: 10/551,414

carboxyl, alkoxycarbonyl, aminoalkyl, *N*-alkylamino, *N*,*N*-dialkylamino, *N*-alkylaminoalkyl, *N*,*N*-dialkylaminoalkyl, *N*-alkyl-*N*-alkoxycarbonylamino and *N*-alkyl-*N*-alkoxycarbonylaminoalkyl,

a group represented by the following formula (IV)

$$-A^3-N(R^4)(R^5)$$
 (IV)

wherein A<sup>3</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-(C=O)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group; and R<sup>4</sup> and R<sup>5</sup> each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, or alkyldiphenylsilyloxyalkyl, and

a group represented by the following formula (V)

$$-A^4$$
-(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>) (V)

wherein A<sup>4</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

R<sup>6</sup> and R<sup>7</sup> each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, N-alkylaminosulfonyl, N,N-dialkylaminosulfonyl, N,N-dialkylaminoalkylcarbonyl, N,N-dialkylaminoalkylcarbonyl or alkyldiphenylsilyloxyalkyl;

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Application No.: 10/551,414

R<sup>3</sup> represents hydrogen;

Ar represents phenylene, which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond; and

G represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein said heterocyclic group is selected from furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, tetrahydroguinolyl, tetrahydrothiazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidiazopyridyl and tetrahydroimidazopyridyl, and wherein the substituent is one or 2 or 3 substituents, which are the same or different, selected from Group (C): halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxycarbonyl, N-alkylamino, N,Ndialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, pyrrolidinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl,

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group selected from the group consisting of indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, 4H-quinolizinyl, quinazolinyl, dihydroquinazolinyl, tetrahydroguinazolinyl, cinnolinyl, tetrahydrocinnolinyl, indolizinyl, tetrahydroindolizinyl, benzothiazolyl, tetrahydrobenzothiazolyl, benzosazolyl, benzoisothiazolyl, benzoisooxazolyl, benzoimidazolyl, naphthyridinyl, tetrahydronaphthyridinyl, thienopyridyl, tetrahydrothienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, thiazolopyridazinyl, tetrahydrothiazolopyridazinyl, pyrrolopyridyl, dihydropyrrolopyridyl, tetrahydropyrrolopyridyl, pyrrolopyrimidinyl, dihydropyrrolopyrimidinyl, pyridopyrimidinyl, tetrahydropyridopyrimidinyl, pyranothiazolyl, dihydropyranothiazolyl, furopyridyl, tetrahydrofuropyridyl, oxazolopyridyl, tetrahydrooxazolopyridyl, oxazolopyridazinyl, tetrahydrooxazolopyridazinyl, pyrrolothiazolyl, dihydropyrrolothiazolyl, pyrrolooxazolyl, dihydropyrrolooxazolyl, thienopyrrolyl, thiazolopyrimidinyl, thiazolooxazolyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, tetrahydroimidazopyridyl, pyrazinopyridazinyl, imidazotriazinyl, oxazolopyridyl, benzooxepinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl, benzotriazepinyl, thienoazepinyl, tetrahydrothienoazepinyl, thienodiazepinyl, thienotriazepinyl, thiazoloazepinyl, and tetrahydrothiazoloazepinyl, which may have a substituent, wherein the substituent represents one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (C):

# Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, *N*-alkylamino, *N*,*N*-dialkylamino, *N*-alkylaminoalkyl, *N*,*N*-

dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof.

## 29.-31. (canceled).

- 32. (previously presented): The compound of formula (I) according to claim 1, which is
- 4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(pyridin-3-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(6-methylbenzothiazol-2-yl)phenylhydrazone,
- 4-(4-methylpiperazin-1-yl)benzaldehyde 4-(6-methylbenzothiazol-2-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(imidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
- 4-hydroxy-3-methoxybenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-[N-(2-hydroxyethyl)-N-methylamino]benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- N,N-dimethyl-4-[4-(oxazol-5-yl)phenylhydrazonomethyl]benzamide,
- 4-(N-methylaminomethyl)thiazol-2-ylcarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 2-dimethylaminomethylthiazole-4-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine)carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
  - 2-hydroxy-5-[4-(oxazol-5-yl)phenylhydrazonomethyl]benzoic acid,
  - 4-[N-(2-fluoroethyl)-N-methylamino]benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
  - 4-(dimethylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

4-(4-methylpiperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-(piperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-(aminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

2-fluoro-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,

2-(4-methylpiperazin-1-yl)-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-fluorobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-aminobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-[4-(oxazol-5-yl)phenylhydrazonomethyl]benzenesulfonamide,

2-dimethylamino-N-{4-[4-(oxazol-5-yl)phenylhydrazonomethyl]phenyl}acetamide,

4-(N-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

thiazole-5-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-(1-aminoethyl)thiazole-2-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,

2-dimethylamino-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,

6-dimethylamino-3-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-(1-aminoethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-(6-bromoimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-(6-chloroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-(6-fluoroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-(imidazo[2,1-b]thiazol-6-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-(imidazo[1,2-a]pyrimidin-2-yl)phenylhydrazone,

4-pyridinecarboxyaldehyde 4-[1-(2-chloroethyl)-2-methyl-1H-imidazol-4-yl]phenylhydrazone,

3-iodo-4-(N-methylaminomethyl)benzaldehyde 4-(pyridin-3-yl)phenylhydrazone,

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

- 4-iodo-3-(N-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 3-chloro-4-(N-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 3-fluoro-4-(N-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone, or

benzimidazole-5-carboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone, or a salt thereof.

- 33. (previously presented): The compound of formula (I) according to claim 1, which is
- 4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(pyridin-3-yl)phenylhydrazone,
- 4-(4-methylpiperazin-1-yl)benzaldehyde 4-(6-methylbenzothiazol-2-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(imidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
- 4-[N-(2-hydroxyethyl)-N-methylamino]benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-(dimethylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-(4-methylpiperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-(piperazin-1-yl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 2-fluoro-4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-fluorobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-aminobenzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-[4-(oxazol-5-yl)phenylhydrazonomethyl]benzenesulfonamide,
- 4-(N-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-(1-aminoethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(6-chloroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(6-fluoroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone,
- 4-pyridinecarboxyaldehyde 4-(imidazo[2,1-b]thiazol-6-yl)phenylhydrazone,

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q90666

Application No.: 10/551,414

4-pyridinecarboxyaldehyde 4-[1-(2-chloroethyl)-2-methyl-1H-imidazol-4-yl]phenylhydrazone,

3-iodo-4-(*N*-methylaminomethyl)benzaldehyde 4-(pyridin-3-yl)phenylhydrazone
4-iodo-3-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone
3-chloro-4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone, or
3-fluoro-4-(*N*-methylaminomethyl)benzaldehyde 4-(oxazol-5-yl)phenylhydrazone, or a salt thereof.

- **34.** (**previously presented**): The compound of formula (I) according to claim 1, which is 4-pyridinecarboxyaldehyde 4-(oxazol-5-yl)phenylhydrazone.
- **35.** (previously presented): The compound of formula (I) according to claim 1, which is 4-pyridinecarboxyaldehyde 4-(6-chloroimidazo[1,2-a]pyridin-2-yl)phenylhydrazone.